Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab

Carrino, JA; McAlindon, TE; Schnitzer, TJ; Guermazi, A; Hochberg, MC; Conaghan, PG; Brown, MT; Burr, A; Fountaine, RJ; Pixton, GC; Viktrup, L; Verburg, KM; West, CR

West, CR (通讯作者)，Pfizer Inc, 445 Eastern Point Rd, Groton, CT 06340 USA.

OSTEOARTHRITIS AND CARTILAGE, 2023; 31 (12): 1612

Abstract

Objective: Due to the risk of rapidly progressive osteoarthritis (RPOA), the phase III studies of subcutaneous (SC) tanezumab in patients with moderat......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索